Quidel has obtained 510(k) clearance from the US Food and Drug Administration (FDA) for its AmpliVue Group B Strep Assay, the second to launch in the handheld, disposable AmpliVue format.

AmpliVue Group B Strep Assay is an instrument-free isothermal assay, which combines helicase dependent amplification (HDA) with Quidel’s well-established expertise in lateral flow technology, to detect Group B Streptococcus (GBS) from enriched broth cultures of specimens from antepartum patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It uses amplification technology with an easy-to-use, handheld device.

"We can now provide the hospital laboratories with another AmpliVue assay for fast, accurate infectious disease testing without the need for additional investments in expensive equipment."

Citing statistics from the US Centers for Disease Control and Prevention, Quidel said that between 10% and 30% of pregnant women carry Group B Streptococcus that can be transmitted to newborns during delivery, and CDC guidelines recommend all pregnant women be tested for infection between 35 and 37 weeks of pregnancy.

Quidel president and CEO Douglas Bryant said: "We can now provide the hospital laboratories with another AmpliVue assay for fast, accurate infectious disease testing without the need for additional investments in expensive equipment."

See Also:

The AmpliVue Group B Strep assay now enables laboratories of all sizes to perform highly sensitive and specific molecular tests.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In 2013, the company launched AmpliVue C difficile assay for the detection of toxigenic Clostridium difficile bacterial DNA.

Both assays are now available for sale throughout the US and Europe, while diagnostic tests for other analytes of interest that will use the novel AmpliVue platform are in development.